Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
12 mrt 2008 - 09:59
Statutaire naam
Crucell N.V.
Titel
Crucell Presents a Compelling Case for Investment at Investor and Analyst Day in London
Bericht
London, March 12, 2008 – Dutch biopharma company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: SW CRX) today presents an update on the company’s performance, strategy for growth acceleration and a review of the company’s pipeline at a meeting for investors and analysts in London. A live audio webcast of the meeting, together with the program and slides of all presentations, will be available on Crucell’s website at www.crucell.com.
Presentations given by senior management and program managers outline a compelling case for investment in Crucell, based on significant solid growth of the company’s vaccines business. Furthermore Crucell enjoys a pipeline of multiple products tailored to address major threats to health and well-being worldwide as well as strong partnerships in vaccine and antibody research. Crucell’s portfolio of unique technologies generating licensing income as well as driving Crucell’s in-house R&D and manufacturing programs will also be discussed.
A clear focus on achieving operational excellence is an integral part of Crucell’s strategy for accelerating growth. A rigorous review of Crucell’s business processes worldwide is being conducted and savings of approximately 15%* on the 2007 cost base are being targeted.
Rationalization is one aspect of Crucell’s ‘Healthy Ambition’ program, which is being implemented throughout the global organization in order to further strengthen the financial health of the company. Cash generated by streamlining business processes and making full use of synergies within the integrated organization will fuel further R&D in targeted areas, thereby enhancing Crucell’s ability to significantly improve human health.
Crucell’s strategic focus remains firmly on fighting infectious diseases through the development, manufacturing and sale of innovative vaccines and antibodies. Infectious diseases represent a major health burden and their impact will increase due to trends such as climate change, globalization, a
Gerelateerde downloads
Datum laatste update: 20 december 2025